Cyfuse Biomedical K.K. (TYO:4892)

Market Cap	7.75B
Revenue (ttm)	54.00M
Net Income (ttm)	-872.00M
Shares Out	7.89M
EPS (ttm)	-108.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	60,500
Average Volume	169,050
Open	974.00
Previous Close	982.00
Day's Range	970.00 - 992.00
52-Week Range	430.00 - 1,412.00
Beta	1.77
RSI	49.70
Earnings Date	May 15, 2025

About Cyfuse Biomedical K.K.

Cyfuse Biomedical K.K. engages in the development, manufacture, and sale of regenerative medicine products in Japan. It develops cellular products in the field of regenerative therapy; and undertakes contract for cellular products for research and development. The company also offers Bio 3D Printer for use in the regeneration of various tissues and organs, such as cartilage and bones, blood vessels, and nerves; regenova, a bio 3D printer for 3D stacking of cells; and S-PIKE that develops 3D-structures from cells. Cyfuse Biomedical K.K. was inco...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2010
• Employees: 21
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4892

Financial Performance

In 2024, Cyfuse Biomedical K.K.'s revenue was 54.00 million, a decrease of -11.48% compared to the previous year's 61.00 million. Losses were -872.00 million, 48.0% more than in 2023.